Melqart Asset Management UK Ltd Sells 31,166 Shares of Abivax SA Sponsored ADR $ABVX

Posted by George Bondi on Jun 17th, 2026

Melqart Asset Management UK Ltd lessened its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report) by 48.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 32,991 shares of the company’s stock after selling 31,166 shares during the quarter. Melqart Asset Management UK Ltd’s holdings in Abivax were worth $4,449,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. EverSource Wealth Advisors LLC increased its holdings in Abivax by 4,612.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after acquiring an additional 369 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Abivax by 661.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after purchasing an additional 344 shares during the last quarter. WPG Advisers LLC grew its position in shares of Abivax by 125.9% during the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after purchasing an additional 253 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its position in shares of Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after purchasing an additional 2,595 shares in the last quarter. Institutional investors own 47.91% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on ABVX. Wolfe Research set a $136.00 target price on Abivax in a research report on Wednesday, June 3rd. Jefferies Financial Group downgraded Abivax from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $160.00 to $90.00 in a research note on Tuesday, June 2nd. Wedbush raised Abivax from an “underperform” rating to a “neutral” rating and decreased their price objective for the stock from $110.00 to $90.00 in a report on Tuesday, June 2nd. BTIG Research reiterated a “buy” rating and set a $150.00 target price on shares of Abivax in a research report on Tuesday. Finally, Barclays raised their target price on shares of Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a report on Tuesday, March 24th. Twelve research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $130.08.

Read Our Latest Stock Analysis on ABVX

Abivax Trading Down 0.8%

Shares of NASDAQ:ABVX opened at $97.50 on Wednesday. Abivax SA Sponsored ADR has a 12 month low of $5.69 and a 12 month high of $148.83. The company has a 50-day moving average price of $115.19 and a 200 day moving average price of $118.66. The company has a market cap of $7.78 billion, a price-to-earnings ratio of -18.71 and a beta of 0.69.

Abivax (NASDAQ:ABVX – Get Free Report) last issued its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to the consensus estimate of $0.40 million. As a group, equities analysts forecast that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

About Abivax

(Free Report)

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.